Honeywell International Inc. (NYSE: HON) is slated to report third quarter 2019 earnings results on Thursday, October 17 before the opening bell. Analysts expect the company to report earnings of $2.01 per share in the quarter. This compares to earnings of $2.03 per share reported last year. Revenue is expected to decrease 15% year-over-year to $9.1 billion.
Last quarter, sales results were impacted by the spin-offs of two business divisions leading to a 15% decline on a reported basis. However, on an organic basis, sales grew 5%, helped by strength in aviation and building solutions.
The strength in the commercial aerospace market might benefit the company in the third quarter. The building solutions and process solutions businesses are also expected to remain healthy in the period. However, weakness in the safety and productivity solutions is likely to dampen results. Economic volatility and currency headwinds are also likely to take a toll on the quarterly numbers.
During the quarter, Honeywell acquired privately-held TruTrak Flight Systems for an undisclosed amount. The acquisition is expected to expand the company’s capabilities in the aviation market.
Also read: JPMorgan Q3 2019 Earnings Preview
In the second quarter of 2019, Honeywell beat earnings estimates while revenues fell short of expectations. Sales dropped 15% year-over-year to $9.24 billion while adjusted EPS rose 9% to $2.10.
For the third quarter of 2019, Honeywell has guided for sales of $9 billion to $9.2 billion, representing an organic growth of 2-4%. EPS is expected to grow 4-6% to $1.97-2.02, excluding spins. For the full year of 2019, the company expects sales to grow 4-6% organically to $36.7 billion to $37.2 billion. EPS is expected to grow 8-10% to $7.95-8.15, excluding spins.
Honeywell’s shares have gained 24% thus far this year. The majority of analysts have rated the stock as Buy and it has an average price target of $186.86.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on
